Based on the successful application of PARP inhibitors in BRCA-deficient breast cancer and EOC, PARP inhibitors are currently being investigated for the treatment of metastatic prostate cancer with promising results [13]. This evidence concerns the gene PARP1 and metastatic prostate carcinoma.